Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis.

Rachel BrodieStephen E LangabeerJohn QuinnMáirín E McMenaminPatrick J Hayden

Published in: Clinical case reports (2019)

Relapse of FLT3-mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.

Keyphrases

acute myeloid leukemia
stem cell transplantation
high dose
allogeneic hematopoietic stem cell transplantation
free survival
case report
low dose
open label
diffuse large b cell lymphoma
multiple myeloma
tyrosine kinase
study protocol